Advanced Innovative Partners (AIP) is a clinical-stage biotechnology company with a highly skilled team that has developed patented platform technologies for the treatment and clinical management of hard-to-cure conditions in
oncology, rare pediatric diseases, infectious diseases, and biomedical countermeasures. AIP's focus on precision medicine and personalized treatments allows for more effective targeting of breast, lung cancers and other solid tumors, while minimizing harm to healthy cells and reducing or
eliminating the risk of side effects.

AIP has the capability and experience to obtain regulatory agency approvals, with several drugs in various stages of development, from early discovery to clinical stage. This makes us a highly attractive investment opportunity, especially considering the substantial capital invested and transactions in therapidly growing radiopharmaceutical industry.

OUR MISSION AND VALUES

Advanced Innovative Partners has the ambition to become a recognized leader in the development of both diagnostic and therapeutic uses in areas of high unmet medical needs.
AIP Purpose

Our
Purpose

AIP Team

Our
Team

AIP Portfolio

Our
Portfolio

Subscribe to our Newsletter

© Copyright 2023 - All Rights Reserved